Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 113

1.

Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer.

Kohrt HE, Houot R, Weiskopf K, Goldstein MJ, Scheeren F, Czerwinski D, Colevas AD, Weng WK, Clarke MF, Carlson RW, Stockdale FE, Mollick JA, Chen L, Levy R.

J Clin Invest. 2019 Jun 3;129(6):2595. doi: 10.1172/JCI129688. Epub 2019 Jun 3. No abstract available.

2.

The NCCN 2019 Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care.

Carlson RW.

J Natl Compr Canc Netw. 2019 May 1;17(5.5):529-530. doi: 10.6004/jnccn.2019.5001. No abstract available.

PMID:
31117029
3.

Policy Challenges and Opportunities to Address Changing Paradigms in Cancer Care Delivery.

Winckworth-Prejsnar K, McCanney J, Schatz AA, Smedley W, Platanias LC, Benitez CM, Newcomer LN, Fitzgerald CL, Carlson RW.

J Natl Compr Canc Netw. 2019 May 1;17(5):424-431. doi: 10.6004/jnccn.2019.7299.

PMID:
31085764
4.

National Comprehensive Cancer Network Infusion Efficiency Workgroup Study: Optimizing Patient Flow in Infusion Centers.

Sugalski JM, Kubal T, Mulkerin DL, Caires RL, Moore PJ, Fiorarancio Fahy R, Gordon JN, Augustyniak CZ, Szymanski GM, Olsen M, Frantz DK, Quinn MA, Kidd SK, Krause DM, Carlson RW, Stewart FM.

J Oncol Pract. 2019 May;15(5):e458-e466. doi: 10.1200/JOP.18.00563. Epub 2019 Apr 9.

PMID:
30964732
5.

Policy Strategies for the "New Normal" in Healthcare to Ensure Access to High-Quality Cancer Care.

Schatz AA, Prejsnar KW, McCanney J, Gutierrez M, Joho S, Alvarnas J, Carlson RW.

J Natl Compr Canc Netw. 2019 Feb;17(2):105-109. doi: 10.6004/jnccn.2018.7267.

PMID:
30787123
6.

Addressing Survivorship in Cancer Care.

McCanney J, Winckworth-Prejsnar K, Schatz AA, Nardi EA, Dwyer AJ, Lieu C, Biru Y, Carlson RW.

J Natl Compr Canc Netw. 2018 Jul;16(7):801-806. doi: 10.6004/jnccn.2018.7054.

PMID:
30006422
7.

The NCCN 23rd Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care.

Carlson RW.

J Natl Compr Canc Netw. 2018 May;16(5S):575-576. No abstract available.

PMID:
29784733
8.

Redefining Quality Measurement in Cancer Care.

Nardi EA, McCanney J, Winckworth-Prejsnar K, Schatz AA, Adelson K, Neubauer M, Smith ML, Walters R, Carlson RW.

J Natl Compr Canc Netw. 2018 May;16(5):473-478. doi: 10.6004/jnccn.2018.7028.

PMID:
29752321
9.

Ensuring Patient Safety and Access in Cancer Care.

Winckworth-Prejsnar K, Nardi EA, McCanney J, Stewart FM, Langbaum T, Gould BJ, Fitzgerald CL, Carlson RW.

J Natl Compr Canc Netw. 2017 Dec;15(12):1460-1464. doi: 10.6004/jnccn.2017.7049.

PMID:
29223983
10.

Implementation Framework for NCCN Guidelines.

Jazieh AR, McClure JS, Carlson RW.

J Natl Compr Canc Netw. 2017 Oct;15(10):1180-1185. doi: 10.6004/jnccn.2017.7020. No abstract available.

PMID:
28982742
11.

Value Tools for Patients in Cancer Care.

Winckworth-Prejsnar K, Lentz LK, Nardi EA, Pruthi S, Fitzgerald CL, Carlson RW.

J Natl Compr Canc Netw. 2017 Jul;15(7):872-877. doi: 10.6004/jnccn.2017.0118.

PMID:
28687575
12.

Developments in Molecular Testing and Biosimilars.

Winckworth-Prejsnar K, Nardi EA, Lentz LK, Crawford JA, Fitzgerald CL, Carlson RW.

J Natl Compr Canc Netw. 2017 Jun;15(6):772-782. doi: 10.6004/jnccn.2017.0109.

PMID:
28596257
13.

Keynote Address: When Breath Becomes Air-As Physician Becomes Patient.

Kalanithi L, Wakelee H, Carlson RW.

J Natl Compr Canc Netw. 2017 May;15(5S):696-698.

PMID:
28515247
14.
15.

Tumor BRCA1 Reversion Mutation Arising during Neoadjuvant Platinum-Based Chemotherapy in Triple-Negative Breast Cancer Is Associated with Therapy Resistance.

Afghahi A, Timms KM, Vinayak S, Jensen KC, Kurian AW, Carlson RW, Chang PJ, Schackmann E, Hartman AR, Ford JM, Telli ML.

Clin Cancer Res. 2017 Jul 1;23(13):3365-3370. doi: 10.1158/1078-0432.CCR-16-2174. Epub 2017 Jan 13.

16.

Financial Relationships With Industry Among National Comprehensive Cancer Network Guideline Authors.

Carlson RW, McClure JS.

JAMA Oncol. 2016 Dec 1;2(12):1660. doi: 10.1001/jamaoncol.2016.4919. No abstract available.

PMID:
27787555
17.

Transforming Prior Authorization to Decision Support.

Newcomer LN, Weininger R, Carlson RW.

J Oncol Pract. 2017 Jan;13(1):e57-e61. doi: 10.1200/JOP.2016.015198. Epub 2016 Oct 24.

PMID:
27756799
18.

Emerging Issues and Opportunities in Health Information Technology.

Nardi EA, Lentz LK, Winckworth-Prejsnar K, Abernethy AP, Carlson RW.

J Natl Compr Canc Netw. 2016 Oct;14(10):1226-1233.

PMID:
27697977
19.

NCCN Framework for Resource Stratification: A Framework for Providing and Improving Global Quality Oncology Care.

Carlson RW, Scavone JL, Koh WJ, McClure JS, Greer BE, Kumar R, McMillian NR, Anderson BO.

J Natl Compr Canc Netw. 2016 Aug;14(8):961-9.

PMID:
27496112
20.

NCCN's Commitment to Medication Safety: The Vincristine Initiative.

Sugalski J, Stewart FM, Carlson RW.

J Natl Compr Canc Netw. 2016 Aug;14(8):959-60.

PMID:
27496111
21.

Value, Access, and Cost of Cancer Care Delivery at Academic Cancer Centers.

Nardi EA, Wolfson JA, Rosen ST, Diasio RB, Gerson SL, Parker BA, Alvarnas JC, Levine HA, Fong Y, Weisenburger DD, Fitzgerald CL, Egan M, Stranford S, Carlson RW, Benz EJ Jr.

J Natl Compr Canc Netw. 2016 Jul;14(7):837-47.

PMID:
27407124
22.

NCCN Evidence Blocks.

Carlson RW, Jonasch E.

J Natl Compr Canc Netw. 2016 May;14(5 Suppl):616-9.

PMID:
27226499
23.

The NCCN 21st Annual Conference: Discussing Key Issues and Updated NCCN Guidelines.

Carlson RW.

J Natl Compr Canc Netw. 2016 May;14(5 Suppl):601-2. No abstract available.

PMID:
27226498
24.

Clinical Breast Examination and Breast Cancer Screening Guideline.

Anderson BO, Bevers TB, Carlson RW.

JAMA. 2016 Apr 5;315(13):1403-4. doi: 10.1001/jama.2016.0686. No abstract available.

PMID:
27046372
25.

NCCN at 20: Forward Momentum.

Carlson RW.

J Natl Compr Canc Netw. 2015 Dec;13(12):1462-3. No abstract available.

PMID:
26656515
26.

Medical Facts vs. Value Judgments.

Carlson RW, McClure JS.

N Engl J Med. 2015 Oct 8;373(15):1480. doi: 10.1056/NEJMc1509650. No abstract available.

PMID:
26444746
27.

NCCN: 20 Years of Improving Patients' Lives.

Carlson RW.

J Natl Compr Canc Netw. 2015 May;13(5 Suppl):629-32.

PMID:
25995416
28.

20 years of advancing the standard of cancer care.

Carlson RW.

J Natl Compr Canc Netw. 2015 May;13(5 Suppl):611-2. No abstract available.

PMID:
25995414
29.

Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105.

Telli ML, Jensen KC, Vinayak S, Kurian AW, Lipson JA, Flaherty PJ, Timms K, Abkevich V, Schackmann EA, Wapnir IL, Carlson RW, Chang PJ, Sparano JA, Head B, Goldstein LJ, Haley B, Dakhil SR, Reid JE, Hartman AR, Manola J, Ford JM.

J Clin Oncol. 2015 Jun 10;33(17):1895-901. doi: 10.1200/JCO.2014.57.0085. Epub 2015 Apr 6.

30.

Optimisation of the continuum of supportive and palliative care for patients with breast cancer in low-income and middle-income countries: executive summary of the Breast Health Global Initiative, 2014.

Distelhorst SR, Cleary JF, Ganz PA, Bese N, Camacho-Rodriguez R, Cardoso F, Ddungu H, Gralow JR, Yip CH, Anderson BO; Breast Health Global Initiative Global Summit on Supportive Care and Quality of Life Consensus Panel Members.

Lancet Oncol. 2015 Mar;16(3):e137-47. doi: 10.1016/S1470-2045(14)70457-7. Review.

PMID:
25752564
31.

NCCN Working Group report: designing clinical trials in the era of multiple biomarkers and targeted therapies.

Venook AP, Arcila ME, Benson AB 3rd, Berry DA, Camidge DR, Carlson RW, Choueiri TK, Guild V, Kalemkerian GP, Kurzrock R, Lovly CM, McKee AE, Morgan RJ, Olszanski AJ, Redman MW, Stearns V, McClure J, Birkeland ML.

J Natl Compr Canc Netw. 2014 Nov;12(11):1629-49.

32.

Solid malignancies in individuals with Down syndrome: a case presentation and literature review.

Bratman SV, Horst KC, Carlson RW, Kapp DS.

J Natl Compr Canc Netw. 2014 Nov;12(11):1537-45.

PMID:
25361800
33.

Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer.

O'Shaughnessy J, Schwartzberg L, Danso MA, Miller KD, Rugo HS, Neubauer M, Robert N, Hellerstedt B, Saleh M, Richards P, Specht JM, Yardley DA, Carlson RW, Finn RS, Charpentier E, Garcia-Ribas I, Winer EP.

J Clin Oncol. 2014 Dec 1;32(34):3840-7. doi: 10.1200/JCO.2014.55.2984. Epub 2014 Oct 27.

PMID:
25349301
34.

Tumor boards: optimizing the structure and improving efficiency of multidisciplinary management of patients with cancer worldwide.

El Saghir NS, Keating NL, Carlson RW, Khoury KE, Fallowfield L.

Am Soc Clin Oncol Educ Book. 2014:e461-6. doi: 10.14694/EdBook_AM.2014.34.e461. Review.

35.

Advancing the standard of cancer care in 2014.

Carlson RW.

J Natl Compr Canc Netw. 2014 May;12(5 Suppl):743-4. No abstract available.

PMID:
24853208
36.

International adaptations of NCCN Clinical Practice Guidelines in Oncology.

Carlson RW, Larsen JK, McClure J, Fitzgerald CL, Venook AP, Benson AB 3rd, Anderson BO.

J Natl Compr Canc Netw. 2014 May;12(5):643-8.

PMID:
24812133
37.

Survivorship: sexual dysfunction (male), version 1.2013.

Denlinger CS, Carlson RW, Are M, Baker KS, Davis E, Edge SB, Friedman DL, Goldman M, Jones L, King A, Kvale E, Langbaum TS, Ligibel JA, McCabe MS, McVary KT, Melisko M, Montoya JG, Mooney K, Morgan MA, O'Connor T, Paskett ED, Raza M, Syrjala KL, Urba SG, Wakabayashi MT, Zee P, McMillian N, Freedman-Cass D; National comprehensive cancer network.

J Natl Compr Canc Netw. 2014 Mar 1;12(3):356-63.

38.

Survivorship: sexual dysfunction (female), version 1.2013.

Denlinger CS, Carlson RW, Are M, Baker KS, Davis E, Edge SB, Friedman DL, Goldman M, Jones L, King A, Kvale E, Langbaum TS, Ligibel JA, McCabe MS, McVary KT, Melisko M, Montoya JG, Mooney K, Morgan MA, O'Connor T, Paskett ED, Raza M, Syrjala KL, Urba SG, Wakabayashi MT, Zee P, McMillian N, Freedman-Cass D; National compresensive cancer network.

J Natl Compr Canc Netw. 2014 Feb;12(2):184-92.

39.

Staying true to a mission: NCCN then and now.

Carlson RW.

J Natl Compr Canc Netw. 2014 Jan;12(1):146-7. No abstract available.

PMID:
24453298
40.

Survivorship: introduction and definition. Clinical practice guidelines in oncology.

Denlinger CS, Carlson RW, Are M, Baker KS, Davis E, Edge SB, Friedman DL, Goldman M, Jones L, King A, Kvale E, Langbaum TS, Ligibel JA, McCabe MS, McVary KT, Melisko M, Montoya JG, Mooney K, Morgan MA, O'Connor T, Paskett ED, Raza M, Syrjala KL, Urba SG, Wakabayashi MT, Zee P, McMillian N, Freedman-Cass D.

J Natl Compr Canc Netw. 2014 Jan;12(1):34-45.

41.

Breast cancer, version 3.2013: featured updates to the NCCN guidelines.

Theriault RL, Carlson RW, Allred C, Anderson BO, Burstein HJ, Edge SB, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Isakoff SJ, Ljung BM, Mankoff DA, Marcom PK, Mayer IA, McCormick B, Pierce LJ, Reed EC, Schwartzberg LS, Smith ML, Soliman H, Somlo G, Ward JH, Wolff AC, Zellars R, Shead DA, Kumar R; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2013 Jul;11(7):753-60; quiz 761.

42.

Advancing the standard of cancer care.

Carlson RW.

J Natl Compr Canc Netw. 2013 May;11(5 Suppl):631-2. No abstract available.

PMID:
23704230
43.

NCCN welcomes 2 new member institutions.

Carlson RW.

J Natl Compr Canc Netw. 2013 Apr 1;11(4):363. No abstract available.

PMID:
23584337
44.

mTOR inhibitors in the treatment of breast cancer.

Vinayak S, Carlson RW.

Oncology (Williston Park). 2013 Jan;27(1):38-44, 46, 48 passim. Review.

45.

Ten years of progress against breast cancer: a partnership of basic and clinical/translational science.

Carlson RW; NCCN Breast Cancer Panel.

J Natl Compr Canc Netw. 2013 Feb 1;11(2):132-6. No abstract available.

PMID:
23411379
46.

Metastatic breast cancer, version 1.2012: featured updates to the NCCN guidelines.

Carlson RW, Allred DC, Anderson BO, Burstein HJ, Edge SB, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Isakoff SJ, Ljung BM, Mankoff DA, Marcom PK, Mayer IA, McCormick B, Pierce LJ, Reed EC, Smith ML, Soliman H, Somlo G, Theriault RL, Ward JH, Wolff AC, Zellars R, Kumar R, Shead DA; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2012 Jul 1;10(7):821-9.

47.

Single cell profiling of circulating tumor cells: transcriptional heterogeneity and diversity from breast cancer cell lines.

Powell AA, Talasaz AH, Zhang H, Coram MA, Reddy A, Deng G, Telli ML, Advani RH, Carlson RW, Mollick JA, Sheth S, Kurian AW, Ford JM, Stockdale FE, Quake SR, Pease RF, Mindrinos MN, Bhanot G, Dairkee SH, Davis RW, Jeffrey SS.

PLoS One. 2012;7(5):e33788. doi: 10.1371/journal.pone.0033788. Epub 2012 May 7.

48.

A randomized trial of combination anastrozole plus gefitinib and of combination fulvestrant plus gefitinib in the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer.

Carlson RW, O'Neill A, Vidaurre T, Gomez HL, Badve SS, Sledge GW.

Breast Cancer Res Treat. 2012 Jun;133(3):1049-56. doi: 10.1007/s10549-012-1997-5. Epub 2012 Mar 15.

49.

Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer.

Kohrt HE, Houot R, Weiskopf K, Goldstein MJ, Scheeren F, Czerwinski D, Colevas AD, Weng WK, Clarke MF, Carlson RW, Stockdale FE, Mollick JA, Chen L, Levy R.

J Clin Invest. 2012 Mar;122(3):1066-75. doi: 10.1172/JCI61226. Epub 2012 Feb 13. Retraction in: J Clin Invest. 2019 Jun 3;129(6):2595.

50.

Breast medical oncologists' use of standard prognostic factors to predict a 21-gene recurrence score.

Kamal AH, Loprinzi CL, Reynolds C, Dueck AC, Geiger XJ, Ingle JN, Carlson RW, Hobday TJ, Winer EP, Goetz MP.

Oncologist. 2011;16(10):1359-66. doi: 10.1634/theoncologist.2011-0048. Epub 2011 Sep 20.

Supplemental Content

Loading ...
Support Center